Results 21 to 30 of about 75 (74)

Oxydation des Tribenzoyl‐apomorphins [PDF]

Berichte der deutschen chemischen Gesellschaft, 1907
n ...
Pschorr, R., Spangenber, O., Spangenberg, O.   +2 more
openaire   +3 more sources

APOMORPHINE‐INDUCED PECKING IN PIGEONS [PDF]

British Journal of Pharmacology and Chemotherapy, 1960
Apomorphine produced persistent pecking in pigeons, the latent period, intensity and duration of which were related to the dose. The ED50 was estimated as 78.1±11.1 μg./kg. On chronic administration of apomorphine there was a significant decrease in latent period and weight which quickly returned to normal on stopping the drug.
P. N. Saxena, B. N. Dhawan
openaire   +3 more sources

The Persistence of Dopamine Dysregulation Syndrome after Pallidal Deep Brain Stimulation in Parkinson's Disease

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Dopamine dysregulation syndrome (DDS) is a debilitating complication of Parkinson's disease (PD) dopamine replacement therapy (DRT) in which patients pathologically and/or compulsively use dopaminergic drugs to treat motor symptoms. Studies examining DDS outcomes following deep brain stimulation (DBS) are limited and have focused on
Natalie David, Stewart A. Factor, Richa Tripathi, Lenora Higginbotham   +3 more
wiley   +1 more source

Health‐Related Quality of Life in Relation to the 5‐2‐1 Criteria in Parkinson's Disease in Sweden

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Device‐aided therapies (DAT) offer alternatives to oral or transdermal dopaminergic treatments in advanced Parkinson's disease (PD), where they can reduce motor fluctuations and dyskinesia and improve health‐related quality of life (HRQoL).
Frida Hjalte, Anna Gustafsson, Jenny Samuelsson, Filip Bergquist, Anders Johansson, Per Odin   +5 more
wiley   +1 more source

Apomorphine in Nervous Affections [PDF]

The Journal of Nervous and Mental Disease, 1885
n ...
openaire   +2 more sources

Cortical Effects of Dopamine Replacement Account for Clinical Response Variability in Parkinson's Disease

Movement Disorders, EarlyView.
Abstract Background Individual variability in clinical response to dopamine replacement therapy (DRT) is a key barrier to efficacious treatment for patients with Parkinson's disease (PD). A better understanding of the neurobiological sources of such interindividual differences is necessary to personalize DRT prescribing, inform future clinical ...
Alex I. Wiesman, Mikkel C. Vinding, Panagiota Tsitsi, Per Svenningsson, Josefine Waldthaler, Daniel Lundqvist   +5 more
wiley   +1 more source

Reply: “Enhancing Parkinson's Disease Research: Recommendations for Addressing Genetic and Environmental Influences in Family History Studies”

Movement Disorders Clinical Practice, EarlyView.
Federica Arienti, Edoardo Monfrini, Alessio Di Fonzo   +2 more
wiley   +1 more source

Bilateral Focused Ultrasound Thalamotomy for Essential Tremor: Clinical Outcomes Compared to Bilateral Deep Brain Stimulation and Probabilistic Lesion Mapping

Movement Disorders, EarlyView.
Abstract Background The efficacy and adverse events (AEs) of bilateral magnetic resonance‐guided focused ultrasound (MRgFUS) thalamotomies for essential tremor (ET) have not been compared to those of deep brain stimulation (DBS). Furthermore, it is uncertain whether second‐side thalamotomies can be positioned differently from the first without ...
Can Sarica, Kazuaki Yamamoto, Christian Iorio‐Morin, Jurgen Germann, Andrew Z. Yang, Brendan Santyr, Michael Colditz, Artur Vetkas, Anton Fomenko, Benjamin Davidson, Franziska Schmidt, Talyta Grippe, Nardin Samuel, Ajmal Zemmar, Oliver Flouty, Cletus Cheyuo, Ghazaleh Darmani, Robert Chen, Alexandre Boutet, Clemens Neudorfer, Mojgan Hodaie, Suneil K. Kalia, Renato P. Munhoz, Alfonso Fasano, Andres M. Lozano   +24 more
wiley   +1 more source

Neuronally‐Derived Extracellular Vesicles Transforming Growth Factor Beta‐1 Levels in Progressive Supranuclear Palsy

Movement Disorders, EarlyView.
Abstract Background Differentiating progressive supranuclear palsy (PSP) from other parkinsonian disorders may be challenging. Objectives To investigate the role of transforming growth factor beta‐1 (TGFβ1) in PSP. Methods A total of 33 PSP, 39 Parkinson's disease (PD), 8 multiple system atrophy (MSA) patients, and 50 healthy controls (HC) were ...
Selena Mimmi, Elvira Immacolata Parrotta, Anna Maria Tolomeo, Domenico Maisano, Valentina Crapella, Elisabetta Pingitore, Khushboo Fatima, Anna Maria Zimbo, Mariagrazia Talarico, Costanza Maria Cristiani, Luana Scaramuzzino, Desirèe Valente, Clara Zannino, Gianni Cuda, Aldo Quattrone, Enrico Iaccino, Andrea Quattrone   +16 more
wiley   +1 more source

Cognitive and Psychiatric Adverse Effects of Foslevodopa/Foscarbidopa in Patients with Parkinson's Disease

Movement Disorders Clinical Practice, EarlyView.
Sacha Brohée, Emmanuel Roze, David Grabli, Hélène Letrillart, Lise Mantisi, Cendrine Foucard, Elodie Hainque, Florence Cormier, Aurélie Méneret, Fabien Hauw   +9 more
wiley   +1 more source